# Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis

> **NCT00695643** · PHASE3 · TERMINATED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 345 (actual)

## Conditions studied

- Diverticulitis

## Interventions

- **DRUG:** Mesalazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00695643
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2011-11
- **Final completion:** 2012-01
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2017-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00695643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00695643, "Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00695643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*